𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naïve patients with chronic hepatitis B

✍ Scribed by M. H. NGUYEN; R. T. GARCIA; H. N. TRINH; H. A. NGUYEN; K. K. NGUYEN; L. H. NGUYEN; B. LEVITT

Book ID
108605773
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
116 KB
Volume
30
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Changes in hepatitis B virus DNA-polymer
Changes in hepatitis B virus DNA-polymerase activity in patients with chronic infection
✍ Dr. A. Alberti; P. Pontisso; G. Realdi 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 427 KB 👁 1 views

## Abstract Levels of serum hepatitis B virus DNA‐polymerase (HBV‐DNAP) were studied longitudinally over variable periods of time in 16 HBV chronic carriers using a modified assay procedure developed to increase reproducibility. Ten patients were tested on a short‐term basis at 3‐ to 6‐hr intervals

Mutations in the core promoter region of
Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B
✍ Kurosaki, Masayuki; Enomoto, Nobuyuki; Asahina, Yasuhiro; Sakuma, Ikuo; Ikeda, T 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 869 KB

The core promoter region of hepatitis B virus genomes regulates transcription of the precore and pregenomic mRNAs encoding hepatitis B e antigen (HBeAg) and core antigen that contain target epitopes for cytotoxic T lymphocytes. The prevalence and clinical significance of mutations in this region wer

Correlation of serum hepatitis B surface
Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B
✍ Myoung Hee Lee; Da Mi Lee; Soon Sun Kim; Jae Youn Cheong; Sung Won Cho 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract Recent studies have suggested that quantifying the serum HBsAg levels can predict the response to pegylated interferon. We aimed to determine the change in serum HBsAg levels during entecavir (ETV) treatment and the correlation with treatment response in chronic HBeAg‐positive and HBeAg

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60